uk ncri flair trial: ibrutinib venetoclax with mrd-directed duration of treatment in cll
Published 9 months ago • 202 plays • Length 2:17Download video MP4
Download video MP3
Similar videos
-
3:00
flair trial: improved outcomes with mrd-guided ibrutinib plus venetoclax in cll compared to fcr
-
1:23
interim analysis of the flair study: efficacy of ibrutinib plus venetoclax in ighv unmutated cll
-
5:34
venetoclax added to ibrutinib in patients with cll with molecular resistance to btki treatment
-
3:24
preventing ibrutinib flare in cll
-
1:05
final analysis of the alpine trial: zanubrutinib vs ibrutinib in r/r cll
-
3:51
phase ib trial of ianalumab and ibrutinib in cll
-
2:49
results from the phase iii echo trial of acalabrutinib plus br in mcl
-
2:57
selecting between ibrutinib, acalabrutinib and zanubrutinib in the frontline setting in cll
-
12:46
fixed duration treatment strategies in cll
-
4:31
sequence of administration of ibrutinib with obinutuzumab in r/r cll patients
-
4:08
phase ib trial of ianalumab plus ibrutinib for cll
-
17:23
updates in cll: key clinical trials in the frontline and r/r setting, pre-clinical data and mrd
-
1:13
overcoming car-t resistance in cll: combining with ibrutinib
-
1:37
causes & management of ibrutinib discontinuation in cll
-
2:14
ibrutinib's role in cll treatment and future outlooks
-
2:57
the cll12 trial of ibrutinib in early stage cll
-
2:06
the role of ibrutinib in the frontline treatment of young patients with cll
-
2:18
first-line ibrutinib and venetoclax in cll
-
2:43
resistance mechanisms of current treatments in cll
-
2:07
efficacy of ibrutinib in the treatment of cll patients with del(17p) and tp53 mutation
-
1:21
evolving management of relapsed cll: uk cll forum analysis of ibrutinib at first relapse
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll